Insight

Sep 11, 2024, 07:24

A roadmap for designing better immunotherapies – Cancer Research Institute

Cancer Research Institute (CRI) made the following post on LinkedIn:

“New findings from researchers, including 2022 William B. Coley Award recipient Dr. Judy Lieberman of Boston Children’s Hospital, indicate that tumors edit multiple genes to avoid recognition by the immune system. Published in Springer Nature Group’s Nature Immunology, the study additionally demonstrates a way to override these edits, by curbing tumor growth in a human-like mouse model of breast cancer, ‘which is notoriously resistant to immunotherapy.’ Discover how this study could provide a roadmap for designing better immunotherapies.”

Read further.
Source: Cancer Research Institute (CRI)/LinkedIn

Boston Children’s Hospital Breast Cancer cancer Cancer research Cancer Research Institute CRI Gene Editing immune system immunotherapy Judy Lieberman Nature Immunology OncoDaily Oncology Springer Nature Group

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer